环介导等温扩增技术诊断高HBV DNA水平的开发与临床验证
研究开发了检测HBV DNA高病毒载量阈值(≥20 000和≥200 000 IU/mL)的环介导等温扩增(LAMP)方法,在法国400例和塞内加尔550例HBV感染者中验证。LAMP检测≥200 000 IU/mL的AUROC为0.95-0.98,敏感度98.0%-98.7%,特异度91.5%-94.6%,方法快速(60分钟)、廉价(8美元/次),可为资源有限地区提供PCR替代方案。
要点
- LAMP可检测8种主要HBV基因型,检测限40-400 IU/mL。
- 诊断≥200 000 IU/mL的AUROC达0.95-0.98,敏感度98%以上。
- 该方法不适用于鉴别低水平病毒血症。
核心结论
- LAMP是简单、快速(60分钟)、廉价(8美元/次)的PCR替代方法,可诊断≥200 000 IU/mL的高病毒血症。
- HBV-LAMP可能通过识别适合抗病毒预防的高危孕妇,助力消除HBV母婴传播。
研究设计与样本
- 设计泛基因型引物,基于保守HBV基因区域。
- 在法国400例和塞内加尔550例HBV感染者中评估LAMP诊断高病毒血症的准确性。
主要发现
- 引物成功检测8种主要HBV基因型/亚型(A1/2/3/B/C/D/E/F),检测限40-400 IU/mL。
- 法国:基于珠提取和实时浊度LAMP诊断≥20 000 IU/mL的AUROC为0.95(95%CI 0.93-0.97),敏感度91.1%,特异度86.0%。
- 法国:诊断≥200 000 IU/mL的AUROC为0.98(95%CI 0.97-0.99),敏感度98.0%,特异度94.6%。
- 塞内加尔:采用免试剂煮沸离心提取和廉价终点荧光检测,诊断≥200 000 IU/mL的AUROC为0.95(95%CI 0.93-0.97),敏感度98.7%,特异度91.5%。
- 性能不随病毒基因型变化,但该方法不适用于鉴别低水平病毒血症。
关键数值与推荐
- WHO定义的临床重要HBV DNA阈值为≥20 000和≥200 000 IU/mL。
- LAMP诊断≥200 000 IU/mL的AUROC为0.95-0.98,敏感度98.0%-98.7%,特异度91.5%-94.6%。
临床怎么用
- 在资源有限地区,HBV-LAMP可用于识别≥200 000 IU/mL的高病毒血症患者。
- 可用于筛查高危孕妇以确定是否适合抗病毒预防,助力消除母婴传播。
局限性
- 该检测不适用于鉴别低水平病毒血症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A massive scale-up of testing and treatment is indicated to globally eliminate hepatitis B virus (HBV) infection. However, access to a polymerase chain reaction (PCR), a key test to quantify HBV DNA levels and determine treatment eligibility, is limited in resource-limited countries. We have developed and evaluated the loop-mediated isothermal amplification (LAMP) assay to diagnose clinically important HBV DNA thresholds defined by the WHO (≥20 000 and ≥ 200 000 IU/mL). METHODS: Pan-genotypic primer sets were designed on conserved HBV gene regions. Accuracy of LAMP to identify highly viraemic patients was evaluated in 400 and 550 HBV-infected people in France and Senegal, respectively. RESULTS: Our primers successfully detected eight major HBV genotypes/sub-genotypes (A1/2/3/B/C/D/E/F) with a detection limit ranging between 40 and 400 IU/mL. In France, the area under the receiver operating characteristic curve (AUROC), sensitivity and specificity of bead-based extraction and real-time turbidimetric LAMP were 0.95 (95% CI 0.93-0.97), 91.1% and 86.0%, respectively, to diagnose HBV DNA ≥20 000 IU/mL; and 0.98 (0.97-0.99), 98.0% and 94.6% for ≥200 000 IU/mL. The performance did not vary by viral genotypes. In Senegal, using a field-adapted method (reagent-free boil-and-spin extraction and inexpensive end-point fluorescence detection), the AUROC, sensitivity and specificity were 0.95 (0.93-0.97), 98.7% and 91.5%, respectively, to diagnose HBV DNA ≥200 000 IU/mL. The assay was not adapted to discriminate low-level viraemia. DISCUSSION: We have developed a simple, rapid (60 min), and inexpensive (US$8/assay) alternative to PCR to diagnose high viraemia ≥200 000 IU/mL. HBV-LAMP may contribute to eliminating HBV mother-to-child transmission by identifying high-risk pregnant women eligible for antiviral prophylaxis in resource-limited countries.
引用
- Vanhomwegen J, Kwasiborski A, Diop A, et al. Development and clinical validation of loop-mediated isothermal amplification (LAMP) assay to diagnose high HBV DNA levels in resource-limited settings. Clin Microbiol Infect. 2021. PMID: 33838304. doi:10.1016/j.cmi.2021.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。